All In Biotech

Drug Trial Radar · NCT04578028

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

A Randomised, Double Blind, Placebo Controlled, Single Centre, Three-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2808 in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Dec 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Aug 19, 2020

Primary completion

Aug 26, 2021

Study completion Oct 7, 2021

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first in human study to determine the safety, tolerability and pharmacokinetics of ONO-2808 in healthy adult participants. The study will be conducted in 3 parts: Part A, a single-ascending dose part with an assessment of the potential food effects in non-Japanese adult participants; Part B, a single dose part to assess the effect of age in non-Japanese elderly participants; and Part C, a multiple-ascending dose part with ONO-2808 administered to healthy subjects.

Conditions

  • Neurodegenerative Diseases

Interventions

  • ONO-2808Drug

    Investigational drug

  • PlaceboDrug

    Placebo drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse events (TEAEs) by severity.Time frame: Part A and B: up to day 7; Part C: up to 17 days.
  2. Serious adverse events (SAEs)Time frame: Part A and B: up to day 7; Part C: up to 17 days.
  3. Vital signsTime frame: Part A and B: up to day 7; Part C: up to 17 days
  4. ECG parametersTime frame: Part A and B: up to day 7; Part C: up to 17 days.
  5. Clinical laboratory testsTime frame: Part A and B: up to day 7; Part C: up to 17 days
  6. Physical examinationTime frame: Part A and B: up to day 7; Part C: up to 17 days
  7. Neurological examinationTime frame: Part A and B: up to day 7; Part C: up to 17 days.
  8. Number of participants with suicidal behaviourTime frame: Part C: up to 17 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International Early Phase Clinical Unit (EPCU)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.